Ziltivekimab is Novo Nordisk's investigational monoclonal antibody targeting interleukin-6 (IL-6), acquired through the July 2021 Corvidia Therapeutics deal for up to $2.1 billion. The drug is not a peptide but represented Novo's central non-GLP-1 growth thesis: reduce systemic inflammation as an independent modifiable risk factor for major adverse cardiovascular events, following the CANTOS canakinumab precedent.
That thesis has struggled through 2026. The Phase 3 ZEUS trial (chronic kidney disease plus cardiovascular disease) missed its primary MACE endpoint in June 2026 and was reported at the ESC Congress on August 30, 2026: ziltivekimab lowered inflammatory markers but did not reduce cardiovascular death, myocardial infarction, or stroke. On Friday September 4, 2026 an independent data monitoring committee recommended early termination of the Phase 3 HERMES (heart-failure event endpoints) and ATHENA (heart-failure quality of life and specific measures) trials as unlikely to succeed; Novo confirmed the terminations Monday September 7, 2026 alongside the positive STEP Young pediatric semaglutide readout, and the mixed pipeline day contributed to a roughly 1.9% Copenhagen share-price decline plus a Barclays price-target cut from DKK 310 to DKK 300.
A separate post-acute heart-failure study of ziltivekimab remains ongoing as the last late-stage indication in the program. Coverage here tracks each Phase 3 readout and Novo's non-GLP-1 diversification. See #novo-nordisk, #zeus-trial, and cardiovascular outcomes for adjacent threads.
Novo Nordisk (NYSE: NVO; Copenhagen: NOVO-B) shares closed at DKK 298.95 in Copenhagen on Monday September 7, 2026 (roughly 1.9% below Friday) after the company's simultaneous release of STEP Young Phase 3 pediatric semaglutide data (40.4% of children aged 6 to under 12 achieved BMI below the obesity threshold at week 68 versus 0% placebo) and confirmation that the HERMES and ATHENA Phase 3 ziltivekimab (anti-IL-6 monoclonal antibody) heart-failure trials had been terminated early after a data monitoring committee ruled the studies unlikely to succeed. Barclays' James Gordon cut the Novo Nordisk price target from DKK 310 to DKK 300 while maintaining an Equal Weight rating. Analyst commentary broadly framed the day as a scientific-engine-versus-diversification tension: the semaglutide franchise continues to add indication paths (pediatric obesity below 12 years is one of the last major label extensions available), while the non-GLP-1 diversification story tied to ziltivekimab now depends primarily on the post-acute heart-failure study that remains ongoing. Detailed STEP Young results will be presented at ObesityWeek 2026 in Washington DC November 14-17.
Novo Nordisk (NYSE: NVO) confirmed Monday September 7, 2026 that it had informed investigators on Friday September 4 that the HERMES and ATHENA Phase 3 trials of ziltivekimab (an anti-IL-6 monoclonal antibody) would end early on the recommendation of an independent data monitoring committee that judged the studies unlikely to succeed. HERMES evaluated ziltivekimab against time to first occurrence of heart failure endpoints including cardiovascular death and heart-failure-linked hospitalisation or urgent visits; ATHENA evaluated the drug's effect on quality of life and other heart-failure-specific measures. The terminations follow the June 2026 ZEUS trial miss (chronic kidney disease plus cardiovascular disease) reported at the ESC Congress August 30, where ziltivekimab lowered inflammation markers but did not reduce major adverse cardiovascular events. A separate post-acute heart failure study of ziltivekimab remains ongoing. Novo shares finished down about 2% on the announcement day (Copenhagen trading open; NYSE closed for Labor Day), with the pediatric semaglutide win offset by the further narrowing of the company's non-GLP-1 growth options.
Novo Nordisk (NYSE: NVO) announced at ESC Congress 2026 that its Phase 3 ZEUS trial of ziltivekimab (an anti-IL-6 monoclonal antibody in development for cardiovascular risk reduction in inflammation-driven disease) failed to reduce major adverse cardiovascular events (MACE) versus placebo in patients with atherosclerotic cardiovascular disease (ASCVD), chronic kidney disease (CKD), and inflammation (hsCRP ≥2 mg/L). The three-component MACE primary endpoint hazard ratio was 0.99 (95% CI 0.88-1.11), despite confirmed IL-6 pathway engagement (reductions in free IL-6 and hsCRP as expected). Safety was broadly similar between arms though serious infections were more frequent on ziltivekimab (consistent with the IL-6 class). NVO shares fell more than 9% on the readout, deepening the widening H1 2026 GLP-1 revenue gap that already sat at $10.2 billion versus Eli Lilly. Novo has committed to continuing the two other cardiovascular outcomes trials (HERMES in heart failure, ARTEMIS post-acute MI) with H1 2027 readouts. The ZEUS miss casts doubt on the broader thesis of anti-inflammatory cardiovascular risk reduction via IL-6 blockade.